tirzepatide surpass-4 versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial Tirzepatide superior to insulin glargine

Eating fewer calories forces the body to use stored fat for energy

Likewise, these extracts exhibited significant anti-inflammatory activity, as demonstrated by the lipoxygenase (LOX) enzyme inhibition assays

Patients with non-alcoholic fatty liver disease (NAFLD) who received tirzepatide showed improvements in liver fibrosis markers and liver stiffness measurements within 612 months

Generally very well-tolerated

Sandra Ramsey, DNP, FNP-C, so your treatment plan reflects both how you feel and how you want to look

These are the same active ingredients found in brand-name medications, but because theyre compounded, theyre made by compounding pharmacies and are not FDA-approved